Hongliang Yao1, Zhulin Yang2, Ziru Liu2, Xiongying Miao2, Leping Yang2, Daiqiang Li3, Qiong Zou4, Yuan Yuan4. 1. Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 2. Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 3. Department of Pathology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 4. Department of Pathology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with metastasis in most patients at diagnosis. The molecular mechanisms associated with its high malignancy have not been fully elucidated. This study investigated the clinicopathological significances of GPC3 and KRT19 expression in PDAC. METHODS: GPC3, KRT19, and CA19-9 protein expression were measured by immunohistochemistry. RESULTS: GPC3 and KRT19 protein levels were overexpressed in PDAC tumors compared to normal pancreatic tissues, benign pancreatic tissues, and peritumoral tissues (P< 0.01). The percentage of positive GPC3 and KRT19 expression were significantly higher in PDAC patients with larger tumor size, poorly differentiated tumor, lymph node metastasis, invasion, and TNM stage III/IV disease than in patients with small tumor size, well-differentiated tumor, no lymph node metastasis and invasion, as well as TNM stage I/II stage disease (P< 0.05 or P< 0.01). Benign pancreatic lesions with positive GPC3 and KRT19 protein expression exhibited dysplasia or intraepithelial neoplasia. Kaplan-Meier survival analysis showed that PDAC patients with positive GPC3 and KRT19 expression survived significantly shorter than patients with negative GPC3 and KRT19 expression (P < 0.05 or P< 0.001). Cox multivariate analysis revealed that positive GPC3 and KRT19 expression were independent poor prognosis factors in PDAC patients. CONCLUSIONS: GPC3 and KRT19 overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC.
OBJECTIVE:Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with metastasis in most patients at diagnosis. The molecular mechanisms associated with its high malignancy have not been fully elucidated. This study investigated the clinicopathological significances of GPC3 and KRT19 expression in PDAC. METHODS:GPC3, KRT19, and CA19-9 protein expression were measured by immunohistochemistry. RESULTS:GPC3 and KRT19 protein levels were overexpressed in PDAC tumors compared to normal pancreatic tissues, benign pancreatic tissues, and peritumoral tissues (P< 0.01). The percentage of positive GPC3 and KRT19 expression were significantly higher in PDAC patients with larger tumor size, poorly differentiated tumor, lymph node metastasis, invasion, and TNM stage III/IV disease than in patients with small tumor size, well-differentiated tumor, no lymph node metastasis and invasion, as well as TNM stage I/II stage disease (P< 0.05 or P< 0.01). Benign pancreatic lesions with positive GPC3 and KRT19 protein expression exhibited dysplasia or intraepithelial neoplasia. Kaplan-Meier survival analysis showed that PDAC patients with positive GPC3 and KRT19 expression survived significantly shorter than patients with negative GPC3 and KRT19 expression (P < 0.05 or P< 0.001). Cox multivariate analysis revealed that positive GPC3 and KRT19 expression were independent poor prognosis factors in PDAC patients. CONCLUSIONS:GPC3 and KRT19 overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC.
Authors: Tessa Ys Le Large; Giulia Mantini; Laura L Meijer; Thang V Pham; Niccola Funel; Nicole Ct van Grieken; Bart Kok; Jaco Knol; Hanneke Wm van Laarhoven; Sander R Piersma; Connie R Jimenez; G Kazemier; Elisa Giovannetti; Maarten F Bijlsma Journal: JCI Insight Date: 2020-08-06
Authors: Ruli Gao; Shanshan Bai; Ying C Henderson; Yiyun Lin; Aislyn Schalck; Yun Yan; Tapsi Kumar; Min Hu; Emi Sei; Alexander Davis; Fang Wang; Simona F Shaitelman; Jennifer Rui Wang; Ken Chen; Stacy Moulder; Stephen Y Lai; Nicholas E Navin Journal: Nat Biotechnol Date: 2021-01-18 Impact factor: 54.908